Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adebrelimab - Atridia

X
Drug Profile

Adebrelimab - Atridia

Alternative Names: HTI-1088; HTI-1316; SHR 1316

Latest Information Update: 05 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Atridia; Jiangsu Hengrui Medicine Co.; Shandong Cancer Hospital and Institute
  • Developer Atridia; Jiangsu Hengrui Medicine Co.; Shandong Cancer Hospital and Institute; Sheng Jing Hospital; Suzhou Suncadia Biopharmaceuticals
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Small cell lung cancer
  • Phase III Non-small cell lung cancer
  • Phase II Cervical cancer; Oesophageal cancer
  • Phase I Solid tumours
  • Clinical Phase Unknown Breast cancer
  • No development reported Cancer; Haematological malignancies

Most Recent Events

  • 01 Apr 2024 Jiangsu Hengrui Medicine plans a phase II trial for Breast cancer (Combination therapy, Neoadjuvant therapy, First-line therapy, In adults, In the elderly) in China (IV, Injection) in April 2024 (NCT06340230)
  • 28 Mar 2024 Shanghai Shengdi Pharmaceuticals plans a phase I/II trial for Non-small cell lung cancer (Combination Therapy, Late-stage disease, Metastatic disease) in China (NCT06335355)
  • 20 Mar 2024 Phase-II clinical trials in Cervical cancer (Combination therapy, Late-stage disease) in China (Parenteral) (NCT06237257)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top